Skip to main content
Log in

„Treat-to-Target“ aus Sicht der Betroffenen

Treat-to-target from the patient perspective

  • Leitthema
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

In der internationalen „Treat-to-Target“-Initiative unter Einbeziehung von Betroffenen werden als Behandlungsziele der rheumatoiden Arthritis (RA) Remission oder geringe Krankheitsaktivität festgelegt. In Deutschland beraten Vertreter der medizinischen Professionen wie Ärzte und medizinische Assistenzberufe unter Einbeziehung der Deutschen Rheuma-Liga, wie diese Ziele adaptiert und konkret zu verwirklichen sind. Dabei ist die Patientenperspektive als Ergebnisvariable zu beachten. Bisher gibt es keinen zusammengesetzten PRO („patient reported outcomes“)-Score, der von der wissenschaftlichen Community allgemein akzeptiert ist und der die Patientenperspektive als primäres Outcome in den Mittelpunkt stellt.

Patient und Arzt sollten gemeinsam über das Therapieziel Remission/niedrige Krankheitsaktivität sowie weitere PROs und die geplante Strategie zum Erreichen dieser Ziele entscheiden. Voraussetzung dafür ist ein ausreichend vorhandener Zeitrahmen. Ein Rheumatologe auf 50.000 erwachsene Einwohner ist das gemeinsame Ziel von Ärzteschaft und Rheuma-Liga. Eine fach- und sektorenübergreifende Behandlung von RA-Patienten ist dabei ebenso zwingend wie der Ausbau der Patientenschulungs-, Informations- und Selbstmanagementprogramme.

Abstract

The international treat-to-target initiative including rheumatoid arthritis (RA) patients has defined remission or alternatively low disease activity as treatment goals. In Germany representatives of the medical profession, such as doctors, nurses and including the Deutsche Rheuma-Liga, are deliberating how to adapt and realize these goals in practice. The patient’s perspective has to be taken into consideration as an outcome variable. Until now no combined patient reported outcome (PRO) score exists which is generally accepted by the scientific community and which puts the patient’s perspective as the main primary outcome.

Patients and doctors ought to decide jointly about the therapy goal remission/low disease activity and about other PROs and the planned strategy to achieve these goals. A precondition is that a sufficient timeframe is still available for this. The joint target of the medical profession and the Deutsche Rheuma-Liga is 1 rheumatologist per 50,000 adult inhabitants. An interdisciplinary and multidisciplinary treatment of RA patients is just as imperative as the expansion of patient training, information and self-management programs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Ahlmén M, Nordenskiöld U, Archenholtz B et al (2005) Rheumatology outcomes: the patient’s perspective. A multicentre focus group interview study of Swedish rheumatoid arthritis patients. Rheumatology (Oxford) 44:105–110

    Google Scholar 

  2. Barrett EM, Scott DGI, Wiles NJ, Symmons DPM (2000) The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology (Oxford) 39:1403–1409

    Google Scholar 

  3. Barton JL, Imboden J, Graf J et al (2010) Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res (Hoboken) 62:857–864

    Article  Google Scholar 

  4. Carr A, Hewlett S, Hughes R et al (2003) Rheumatology outcomes: the patient’s perspective. J Rheumatol 30:880–883

    PubMed  Google Scholar 

  5. Wit MPT de, Smolen JS, Gossec L, Heijde DMFM van der (2011) Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis 70:891–895

    Article  PubMed  Google Scholar 

  6. Dougados M (2005) It’s good to feel better but it’s better to feel good. J Rheumatol 32:1–2

    PubMed  Google Scholar 

  7. Food and Drug Administration (2009) Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf

  8. Gossec L, Dougados M, Rincheval N et al (2009) Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 68:1680–1685

    Article  PubMed  CAS  Google Scholar 

  9. Gossec L, Paternotte S, Aanerud GJ et al (2011) Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 70:935–942

    Article  PubMed  CAS  Google Scholar 

  10. Härter M, Loh A, Spies C (Hrsg) (2005) Gemeinsam entscheiden – erfolgreich behandeln: Neue Wege für Ärzte und Patienten im Gesundheitswesen. Deutscher Ärzte-Verlag, Köln

  11. Hazes JM, Taylor P, Strand V et al (2010) Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology (Oxford) 49:1900–1910

    Google Scholar 

  12. Heiberg T, Austad C, Kvien TK, Uhlig T (2011) Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to other patient-reported outcomes in a register of patients with rheumatoid arthritis. Ann Rheum Dis 70:1080–1082

    Article  PubMed  Google Scholar 

  13. Hewlett S, Carr M, Ryan S et al (2005) Outcomes generated by patients with rheumatoid arthritis: how important are they? Musculoskeletal Care 3:131–142

    Article  PubMed  Google Scholar 

  14. Hewlett S, Sanderson T, May J et al (2011) ‚I’m hurting, I want to kill myself’: rheumatoid arthritis flare is more than a high joint count – an international patient perspective on flare where medical help is sought. Rheumatology (Oxford). [Epub ahead of print]

  15. Kalyoncu U, Dougados M, Daurès J-P, Gossec L (2009) Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 68:183–190

    Article  PubMed  CAS  Google Scholar 

  16. Kavanaugh A, Lee SJ, Weng HH et al (2010) Patient-derived joint counts are a potential alternative for determining Disease Activity Score. J Rheumatol 37:1035–1041

    Article  PubMed  Google Scholar 

  17. Keystone EC (2010) Are physician-derived joint counts obsolete? J Rheumatol 37:883–884

    Article  PubMed  Google Scholar 

  18. Kirwan JR, Newman S, Tugwell PS et al (2009) Progress on incorporating the patient perspective in outcome assessment in rheumatology and the emergence of life impact measures at OMERACT 9. J Rheumatol 36:2071–2076

    Article  PubMed  Google Scholar 

  19. Krauth C, Rieger J, Mau W et al (2003) Gesundheitsökonomische Analyse der langfristigen Auswirkungen eines Schulungsprogramms für Patienten mit chronischer Polyarthritis. In: Petermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. Roderer, Regensburg, S 293–307

  20. Kvamme MK, Kristiansen IS, Lie E, Kvien TK (2010) Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 37:26–31

    Article  PubMed  Google Scholar 

  21. Martin RW, Head AJ, René J et al (2008) Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician. J Rheumatol 35:618–624

    PubMed  Google Scholar 

  22. Maurischat C, Ehlebracht-König I, Kühn A, Bullinger M (2005) Strukturelle Validität des Short Form 36 (SF-36) bei Patienten mit entzündlich-rheumatischen Erkrankungen. Z Rheumatol 64:255–264

    Article  PubMed  CAS  Google Scholar 

  23. McPherson KM, Brander P, Taylor WJ, McNaughton HK (2001) Living with arthritis – what is important? Disabil Rehabil 23:706–721

    Article  PubMed  CAS  Google Scholar 

  24. Pincus T, Yazici Y, Bergman MJ (2009) RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am 35:773–778

    Article  PubMed  Google Scholar 

  25. Schett G (o J) persönliche Mitteilung

  26. Smolen JS, Aletaha D, Bijlsma JWJ et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69:631–637

    Article  PubMed  Google Scholar 

  27. Sokka T, Häkkinen A, Krishnan E, Hannonen P (2004) Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis 63:494–497

    Article  PubMed  CAS  Google Scholar 

  28. Stucki G, Cieza A, Geyh S et al (2004) ICF Core Sets for rheumatoid arthritis. J Rehabil Med Suppl 44:87–93

    Article  Google Scholar 

  29. Ten Klooster PM, Veehof MM, Taal E et al (2007) Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment. Ann Rheum Dis 66:1485–1490

    Article  Google Scholar 

  30. Tuyl LHD van, Plass AMC, Lems WF et al (2008) Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis. Rheumatology (Oxford) 47:1571–1576

    Google Scholar 

  31. Wolfe F, Michaud K (2007) Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients‘ treatment choices. Arthritis Rheum 56:2135–2142

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E. Gromnica-Ihle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gromnica-Ihle, E., Rink, M. „Treat-to-Target“ aus Sicht der Betroffenen. Z. Rheumatol. 70, 678–684 (2011). https://doi.org/10.1007/s00393-011-0773-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-011-0773-y

Schlüsselwörter

Keywords

Navigation